Impact of Zinc Supplementation in Low Birth Weight Infants on Severe Morbidity, Mortality and Zinc Status: A Randomized Controlled Trial

This study has been completed.
Sponsor:
Collaborators:
World Health Organization
Kenneth and Linda Pollin Foundation,USA
Information provided by:
Society for Applied Studies
ClinicalTrials.gov Identifier:
NCT00272142
First received: January 3, 2006
Last updated: September 2, 2009
Last verified: September 2009
  Purpose

There are currently no interventions available to substantially reduce the incidence of low birth weight (LBW) apart from increasing the age at marriage, maternal iron supplementation and possibly improved energy intakes.

The current view of the medical and public health community in India is that the immediate focus should be on promoting survival and development of low birth weight infants who have nearly a 6 to 7 fold higher mortality during infancy than those with normal birth weight.

Low serum zinc is associated with increased incidence of diarrhea and pneumonia. There is sufficient evidence in under-threes that during acute illness, zinc supplementation (1-2 recommended dietary allowance [RDA]) reduces incidence of all episodes of diarrhea, severe diarrhea and pneumonia. A number of initial published trials also show significant effect of zinc treatment on pneumonia. With the large and consistent effects of zinc supplementation on the incidence and severity of infections, an effect on child mortality is likely.

Available literature suggests the distinct possibility of reduced neonatal and infant mortality in LBWs receiving 1 RDA of zinc daily. A pilot study in India showed a 54% reduction in mortality in LBW infants. These findings were based on a very small sample and therefore considered insufficient to change policy.

A positive impact in the proposed study will provide an important tool for reduction of infant mortality which is currently stagnant and government acceptance for such a program is likely to be very high. We, the researchers at the Society for Applied Studies, believe this study has the potential for decreasing infant mortality from its current level.


Condition Intervention
Diarrhea
Respiratory Infection
Low Birth Weight
Drug: Zinc
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Impact of Zinc Supplementation in Low Birth Weight Infants on Severe Morbidity, Mortality and Zinc Status: A Randomized Controlled Trial

Resource links provided by NLM:


Further study details as provided by Society for Applied Studies:

Primary Outcome Measures:
  • all cause hospitalizations in comparison to infants receiving placebo. [ Time Frame: November 2004 to August 2007 ]
  • illnesses requiring visits to healthcare providers. [ Time Frame: November 2004 to August 2007 ]

Secondary Outcome Measures:
  • cause specific hospitalizations for diarrhea and acute lower respiratory infections [ Time Frame: November 2004 to August 2007 ]
  • cause specific health care provider visits for illness [ Time Frame: November 2004 to August 2007 ]
  • all cause mortality in the two groups [ Time Frame: November 2004 to August 2007 ]
  • the proportion of stunted or underweight infants at end study [ Time Frame: November 2004 to August 2007 ]
  • plasma zinc in a subgroup [ Time Frame: November 2004 to August 2007 ]
  • prevalence of diarrheal and respiratory morbidity [ Time Frame: November 2004 to August 2007 ]

Estimated Enrollment: 2000
Study Start Date: January 2005
Study Completion Date: August 2007
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)
Detailed Description:

A double blind, randomized, placebo controlled trial is being conducted in which the unit of randomization is 14-28 days old infants. Infants in the intervention group receive 1 RDA of elemental zinc compared to placebo in the control group, from the day of enrollment till 12 months of age.

Infants for enrollment are being identified through daily screening of newborns in two hospitals. Eligible infants are visited at home for enrollment when aged 14-28 days. The mother is trained in supplement administration. A total of 2000 infants will be enrolled.

Infants in the intervention group are being administered a dispersible tablet daily containing 1 RDA of elemental zinc (5 mg elemental zinc per day in infants aged 14 days to 6 months and 10 mg per day for infants older than 6 months) daily till 12 months of age. The placebo contains plain glucose but is similar in taste, color and consistency to the zinc tablet. The tablets are packaged in strips containing 15 tablets each.

Monthly supplies of the supplement are given to the caregiver to be kept at home. The supplement is administered by the caregiver (usually the mother) herself and the method of administration is taught at the time of enrollment. At the end of every four weeks the monitor collects the strips for the previous month and records the supplement intake for the previous month by examining the strips and querying the caregiver.

Three monthly morbidity visits are conducted by a field investigator to obtain information on the hospitalizations and their causes in the last 3 months, healthcare provider visits in the last 1 month, illnesses for which these were made and severity of these illnesses, diarrhea and respiratory morbidity in the previous 24 hours, week and month. If the infant has been hospitalized in the last 3 months, a hospitalization form is filled to ascertain the reason for hospitalization. In case of deaths, an interview is conducted with the caregiver and a verbal autopsy form is filled.

Blood specimens for estimation of plasma zinc, copper and ferritin are being obtained in 15% randomly selected children at baseline and at end study.

Weights and lengths are being obtained in a subset of children at birth, 3, 6, 9 and 12 months.

  Eligibility

Ages Eligible for Study:   up to 28 Days
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Infants aged 14 to 28 days born after 37 weeks of gestation and weighing less than or equal to 2.5 kg at birth (<10th percentile of the National Center for Health Statistics [NCHS] median birth weight)
  • Either sex
  • Resides within 7 km of the hospital

Exclusion Criteria:

  • Likely to leave the area of residence within 6 months of enrollment
  • Congenital malformations, congenital heart disease, metabolic disorders, renal diseases, etc.
  • Non consent for participation
  • Illness requiring hospitalization
  • Twins
  • Preterm
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00272142

Locations
India
Society for Applied Studies
New Delhi, Delhi, India, 110017
Sponsors and Collaborators
Society for Applied Studies
World Health Organization
Kenneth and Linda Pollin Foundation,USA
Investigators
Principal Investigator: Nita Bhandari, PhD Society for Applied Studies
  More Information

Publications:
Responsible Party: Nita Bhandari, Society for Applied Studies
ClinicalTrials.gov Identifier: NCT00272142     History of Changes
Other Study ID Numbers: HNI 04002, C6.181.488
Study First Received: January 3, 2006
Last Updated: September 2, 2009
Health Authority: India: Ministry of Health

Keywords provided by Society for Applied Studies:
mortality
hospitalization
diarrhea
respiratory infection
low birth weight
morbidity

Additional relevant MeSH terms:
Birth Weight
Diarrhea
Respiratory Tract Infections
Body Weight
Signs and Symptoms
Signs and Symptoms, Digestive
Infection
Respiratory Tract Diseases
Zinc
Trace Elements
Micronutrients
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 20, 2014